Tailored Therapy for Breast Cancer in Very Young Women

作者: Jan Erik Duus , Shelly S. Lo , Kathy S. Albain

DOI: 10.1007/978-3-540-28266-2_18

关键词:

摘要: The heterogeneity of breast cancer is well understood both biologically and in the practice setting. On one hand, it not uncommon for some patients to survive years despite presence widely advanced or metastatic disease. In contrast, with localized tumors may relapse rapidly adequate surgical medical treatment. Age has long been considered have a strong association this varying clinical behavior, older being more likely indolent disease, younger tending aggressive course. Recognizing unique nature disease population, 1993 National Institutes Health (NIH) sponsored conference discuss various aspects women. consensus statements were published Journal Cancer Institute Monographs [99]. Since then, multiple panels acknowledged young age as an adverse prognostic factor [29, 43, 45], although controversy regarding treatment still exists. Thus, appropriate consider special scenario young, premenopausal patient, specific focus on whether therapy should be tailored different manner than postmenopausal patients.

参考文章(111)
G M Swanson, C S Lin, Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. Journal of The National Cancer Institute Monographs. pp. 69- 77 ,(1994)
D C Allred, G M Clark, K S Albain, Breast cancer outcome and predictors of outcome: are there age differentials? Journal of The National Cancer Institute Monographs. pp. 35- 42 ,(1994)
Malin M, Allen S, Age differences in the psychosocial problems encountered by breast cancer patients. Journal of The National Cancer Institute Monographs. pp. 191- ,(1994)
D S Hawkins, G W Demers, D A Galloway, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Research. ,vol. 56, pp. 892- 898 ,(1996)
Niels Kroman, Andrew Tutt, Maj-Britt Jensen, Jan Wohlfahrt, Henning T Mouridsen, Per Kragh Andersen, Mads Melbye, Gillian Ross, Factors influencing the effect of age on prognosis in breast cancer: population based study Commentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer BMJ. ,vol. 320, pp. 474- 479 ,(2000) , 10.1136/BMJ.320.7233.474
B G Haffty, D Fischer, M Rose, M Beinfield, C McKhann, Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. Journal of Clinical Oncology. ,vol. 9, pp. 997- 1003 ,(1991) , 10.1200/JCO.1991.9.6.997
A. de la Rochefordière, F. Campana, J. Fenton, J.R. Vilcoq, A. Fourquet, B. Asselain, S.M. Scholl, P. Pouillart, J.-C. Durand, H. Magdelenat, Age as prognostic factor in premenopausal breast carcinoma. The Lancet. ,vol. 341, pp. 1039- 1043 ,(1993) , 10.1016/0140-6736(93)92407-K
A S Lichter, M E Lippman, D N Danforth, T d'Angelo, S M Steinberg, E deMoss, H D MacDonald, C M Reichert, M Merino, S M Swain, Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. Journal of Clinical Oncology. ,vol. 10, pp. 976- 983 ,(1992) , 10.1200/JCO.1992.10.6.976